Stefan Kubicek

Targeting metabolic enzymes in the cell’s nucleus
Research Center for Molecular Medicine of the Austrian Academy of Sciences (Austria)


Stefan Kubicek, PhD., is an Austrian citizen born 1978 in Vienna. He studied synthetic organic chemistry at the Vienna University of Technology and the Swiss Federal Institute of Technology (with François Diederich, ETH Zürich). For his PhD in Molecular Biology he developed the first specific histone methyltransferase inhibitor at the Institute of Molecular Pathology IMP Vienna (advisor Thomas Jenuwein). He then spent 3 years as a postdoctoral fellow at the Broad Institute of Harvard and MIT in Cambridge, MA, USA (Chemical Biology Program, Stuart Schreiber laboratory). He joint CeMM in 2010 where he headed the Platform Austria for Chemical Biology, the Christian Doppler laboratory for Chemical Epigenetics and Antiinfectives, a public-private partnership, Boehringer Ingelheim and Haplogen (2013-2019), and the Molecular Discovery Platform (since 2017). Research in the Kubicek lab is funded by the Austrian Academy of Sciences, the European Research Council ERC, the Juvenile Diabetes Research Foundation JDRF, the Austrian Federal Ministry of Science, Research and Economy and the National Foundation for Research, Technology, and Development, the Vienna Science and Technology Fund WWTF, and the Austrian Science Fund FWF. Stefan Kubicek studies chromatin, epigenetics and small molecules that change cell fates in oncology and diabetes with a particular focus on metabolism in the cell’s nucleus.


About his talk: Targeting metabolic enzymes in the cell’s nucleus

Metabolic activities in the nucleus comprise classical chromatin modifiers and additional enzymes of more central metabolic pathways. We use a combination of proteomics, metabolomics and fluorescent reporter approaches to comprehensively understand these metabolic activities. We further apply these fluorescent reporters in chemical and genetic screens for factors altering chromatin accessibility, protein localization and protein abundance. These approaches aim at identifying therapeutic targets and small molecule modulators of cell fate decisions in diabetes and cancer.